TRVI
Income statement / Annual
Last year (2024), Trevi Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Trevi Therapeutics, Inc.'s net income was -$47.91 M.
See Trevi Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$123,000.00
|
$43,000.00
|
$50,000.00
|
$47,000.00
|
$39,000.00
|
$23,000.00
|
$0.00
|
$4,000.00
|
| Gross Profit |
$0.00
|
-$123,000.00
|
-$43,000.00
|
-$50,000.00
|
-$47,000.00
|
-$39,000.00
|
-$23,000.00
|
$0.00
|
-$4,000.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$39.38 M
|
$23.68 M
|
$19.83 M
|
$22.98 M
|
$22.33 M
|
$19.34 M
|
$14.07 M
|
$6.10 M
|
$6.91 M
|
| General & Administrative Expenses |
$12.15 M
|
$9.95 M
|
$10.07 M
|
$9.49 M
|
$10.16 M
|
$7.31 M
|
$4.34 M
|
$2.14 M
|
$1.66 M
|
| Selling & Marketing Expenses |
$0.00
|
$287,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$50,000.00
|
| Selling, General & Administrative Expenses |
$12.15 M
|
$10.24 M
|
$10.07 M
|
$9.49 M
|
$10.16 M
|
$7.31 M
|
$4.34 M
|
$2.14 M
|
$1.71 M
|
| Other Expenses |
$0.00
|
$0.00
|
$719,000.00
|
-$375,000.00
|
-$287,000.00
|
$577,000.00
|
-$2.24 M
|
-$24,000.00
|
$0.00
|
| Operating Expenses |
$51.52 M
|
$33.92 M
|
$29.91 M
|
$32.48 M
|
$32.49 M
|
$26.65 M
|
$18.41 M
|
$8.24 M
|
$8.62 M
|
| Cost And Expenses |
$0.00
|
$33.92 M
|
$29.91 M
|
$32.48 M
|
$32.49 M
|
$26.65 M
|
$18.41 M
|
$8.24 M
|
$8.63 M
|
| Interest Income |
$0.00
|
$4.75 M
|
$1.74 M
|
$10,000.00
|
$178,000.00
|
$792,000.00
|
$156,000.00
|
$69,000.00
|
$2.61 M
|
| Interest Expense |
$0.00
|
$391,000.00
|
$780,000.00
|
$1.20 M
|
$456,000.00
|
$0.00
|
$174,000.00
|
$3.34 M
|
$0.00
|
| Depreciation & Amortization |
-$3.58 M
|
$123,000.00
|
$43,000.00
|
$50,000.00
|
$47,000.00
|
$39,000.00
|
$23,000.00
|
$4,000.00
|
$4,000.00
|
| EBITDA |
-$51.52 M |
-$33.80 M |
-$29.86 M |
-$32.43 M |
-$32.44 M |
-$26.61 M |
-$18.39 M |
-$8.19 M |
-$8.62 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.58 M
|
$4.83 M
|
$719,000.00
|
-$1.49 M
|
-$287,000.00
|
$577,000.00
|
-$2.26 M
|
-$4.65 M
|
-$2.47 M
|
| Income Before Tax |
-$47.94 M
|
-$29.10 M
|
-$29.19 M
|
-$33.96 M
|
-$32.78 M
|
-$26.07 M
|
-$20.67 M
|
-$12.89 M
|
-$11.10 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$30,000.00
|
-$32,000.00
|
-$36,000.00
|
-$21,000.00
|
-$18,000.00
|
-$18,000.00
|
-$124,000.00
|
-$26,000.00
|
-$8,000.00
|
| Net Income |
-$47.91 M
|
-$29.07 M
|
-$29.15 M
|
-$33.94 M
|
-$32.76 M
|
-$26.05 M
|
-$20.55 M
|
-$12.86 M
|
-$11.09 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.47 |
-0.29 |
-0.45 |
-1.49 |
-1.81 |
-2.22 |
-2.29 |
-1.43 |
-0.69 |
| EPS Diluted |
-0.47 |
-0.29 |
-0.45 |
-1.49 |
-1.81 |
-2.22 |
-2.29 |
-1.43 |
-0.69 |
| Weighted Average Shares Out |
$101.04 M
|
$99.03 M
|
$64.54 M
|
$22.84 M
|
$18.06 M
|
$11.74 M
|
$8.97 M
|
$8.97 M
|
$16.14 M
|
| Weighted Average Shares Out Diluted |
$101.04 M
|
$99.03 M
|
$64.54 M
|
$22.84 M
|
$18.06 M
|
$11.74 M
|
$8.97 M
|
$8.97 M
|
$16.14 M
|
| Link |
|
|
|
|
|
|
|
|
|
